The most common treatment option for AML is chemotherapy to kill the cancerous cells. Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naïve) and are ineligible to undergo intensive chemotherapy. If licenced, guadecitabine would offer a new treatment option for patients that cannot tolerate the standard of care chemotherapy treatments.
Paclitaxel formulated as albumin bound nanoparticles (Nab-paclitaxel) in combination with gemcitabine is being developed as a treatment option for patients with pancreatic cancer who have undergone surgery to increase the chances of being cured (‘adjuvant therapy’). Both drugs are chemotherapies already being used to treat metastatic pancreatic cancer and other types of cancers and are administered by injection.